Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Stage II-III HER2-positive Breast Cancer Patients Who Have Poor Outcomes After Treatment With Trastuzumab and Pertuzumab
Latest Information Update: 14 Sep 2022
At a glance
- Drugs ARX 788 (Primary) ; Pyrotinib (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 30 Jul 2022 Planned initiation date changed from 10 Aug 2021 to 31 Jul 2022.
- 30 Jul 2022 Status changed from not yet recruiting to recruiting.
- 04 Aug 2021 New trial record